Compared with standard care, carbidogopa levodopa enteral suspension is more cost-effective.

Published Date: 16 Nov 2023

An incremental cost-effectiveness ratio of $7711/QALY was found in a real-world study comparing the cost-effectiveness of carbidoglopaprofenopa levodopa enteral suspension for Parkinson disease to standard care.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Examines Office-Based Transperineal Prostate Biopsies Methodology.

2.

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.

3.

Is a $2,000 Whole-Body MRI Worth It?

4.

Surgery may not be necessary to treat invasive breast cancer

5.

Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot